These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 2344886

  • 1. High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients.
    Lejeune C, Tubiana N, Gastaut JA, Maraninchi D, Richard B, Launay MC, Sainty D, Sebahoun G, Carcassonne Y.
    Eur J Haematol; 1990 Apr; 44(4):240-3. PubMed ID: 2344886
    [Abstract] [Full Text] [Related]

  • 2. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P.
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [Abstract] [Full Text] [Related]

  • 3. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
    Koller CA, Kantarjian HM, Feldman EJ, O'Brien S, Rios MB, Estey E, Keating M.
    Cancer; 1999 Dec 01; 86(11):2246-51. PubMed ID: 10590364
    [Abstract] [Full Text] [Related]

  • 4. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
    Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Planker M, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner T.
    Semin Oncol; 1987 Jun 01; 14(2 Suppl 1):73-7. PubMed ID: 3473685
    [Abstract] [Full Text] [Related]

  • 5. Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia.
    Keskin A, Tombuloğlu M, Atamer MA, Büyükkeçeci F.
    Acta Haematol; 1994 Jun 01; 92(1):14-7. PubMed ID: 7985476
    [Abstract] [Full Text] [Related]

  • 6. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia.
    Paciucci PA, Cuttner J, Holland JF.
    Am J Hematol; 1990 Sep 01; 35(1):22-5. PubMed ID: 2202204
    [Abstract] [Full Text] [Related]

  • 7. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH.
    J Clin Oncol; 1997 Aug 01; 15(8):2780-5. PubMed ID: 9256119
    [Abstract] [Full Text] [Related]

  • 8. High-dose cytosine arabinoside and etoposide in the treatment of relapsed or refractory adult leukemia.
    Gryn J, Conroy J, Topolsky D, Crilley P, Kahn SB, Bulova S, Weiss J, Brodsky I.
    Am J Clin Oncol; 1991 Feb 01; 14(1):52-4. PubMed ID: 1987740
    [Abstract] [Full Text] [Related]

  • 9. Mitoxantrone for refractory and relapsed acute leukemia.
    Bezwoda WR, Bernasconi C, Hutchinson RM, Winfield DA, de Bock R, Mandelli F.
    Cancer; 1990 Aug 01; 66(3):418-22. PubMed ID: 2194640
    [Abstract] [Full Text] [Related]

  • 10. Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia.
    Linkesch W, Thaler J, Gattringer C, Konwalinka G.
    Haematol Blood Transfus; 1990 Aug 01; 33():330-2. PubMed ID: 2323638
    [No Abstract] [Full Text] [Related]

  • 11. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N, Sarper N, Devecioğlu O, Anak S, Eryilmaz E, Can M, Yenilmez H, Ağaoğlu L, Gedikoğlu G.
    Turk J Pediatr; 2000 Aug 01; 42(3):198-204. PubMed ID: 11105617
    [Abstract] [Full Text] [Related]

  • 12. Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia.
    Liso V, Specchia G, Capalbo S, Pavone V, Iacobazzi A, Iaculli ML, Dione R, Pansini N.
    Acta Haematol; 1992 Aug 01; 87(1-2):54-7. PubMed ID: 1585771
    [Abstract] [Full Text] [Related]

  • 13. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia.
    Walters RS, Kantarjian HM, Keating MJ, Plunkett WK, Estey EH, Andersson B, Beran M, McCredie KB, Freireich EJ.
    Cancer; 1988 Aug 15; 62(4):677-82. PubMed ID: 3165047
    [Abstract] [Full Text] [Related]

  • 14. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
    Kern W, Schleyer E, Unterhalt M, Wörmann B, Büchner T, Hiddemann W.
    Cancer; 1997 Jan 01; 79(1):59-68. PubMed ID: 8988727
    [Abstract] [Full Text] [Related]

  • 15. [High doses of cytosine arabinoside in the treatment of patients with acute relapsing or refractory leukemia].
    Lobato-Mendizábal E, Ruiz-Argüelles GJ, Marín-López A.
    Rev Invest Clin; 1989 Jan 01; 41(2):139-45. PubMed ID: 2675236
    [Abstract] [Full Text] [Related]

  • 16. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia.
    Kantarjian HM, Walters RL, Keating MJ, Estey EH, O'Brien S, Schachner J, McCredie KB, Freireich EJ.
    Cancer; 1990 Jan 01; 65(1):5-8. PubMed ID: 2293869
    [Abstract] [Full Text] [Related]

  • 17. Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone.
    Bolaman Z, Köseoğlu M, Ayyildiz O, Kadiköylü G, Sönmez HM, Demir S, Müftüoğlu E.
    Haematologia (Budap); 2002 Jan 01; 32(1):49-57. PubMed ID: 12243555
    [Abstract] [Full Text] [Related]

  • 18. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
    Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, Briel J, Jones RJ, Wright JJ, Colevas AD.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4467-73. PubMed ID: 17671131
    [Abstract] [Full Text] [Related]

  • 19. A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia.
    Rosen PJ, Rankin C, Head DR, Boldt DH, Luthardt FW, Norwood T, Pugh RP, Karanes C, Appelbaum FR.
    Leuk Res; 2000 Mar 01; 24(3):183-7. PubMed ID: 10738999
    [Abstract] [Full Text] [Related]

  • 20. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
    Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner T.
    Blood; 1987 Mar 01; 69(3):744-9. PubMed ID: 3469002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.